Plasma viral load threshold for sustaining intrahost HIV type 1 evolution.

The objective of the present study was to determine if natural suppression of plasma viremia below the detection limit of commercial assays (50-80 copies HIV-1 RNA/ml) can contain the HIV-1 evolution. HIV-1 quasispecies complexity in PBMC DNA was assessed in the env gene at two time points in 14 long-term nonprogressors (LTNPs). Sequence changes consistent with viral evolution was found in all patients with a median plasma RNA viral load >100 copies/ml. Evidence of low-level viral evolution was detected in two of four patients with intermittent viremia and a median plasma HIV-1 RNA load of >80 copies/ml. No significant evolution was observed in the three LTNPs with persistent viral suppression below the detection limit. Overall, a significant positive correlation (p < 0.001) was observed between viral evolution and plasma RNA viral load in the LTNPs analyzed. These results suggest that the detection limit of ultrasensitive viremia assays could represent an important threshold below which intrahost HIV-1 evolution does not occur.

[1]  B. Korber,et al.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease , 1997, Journal of virology.

[2]  E. G. Shpaer,et al.  Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. , 1993, Science.

[3]  M P Busch,et al.  Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo , 1997, Journal of virology.

[4]  C. Rouzioux,et al.  Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Vicario,et al.  A subset of human immunodeficiency virus type 1 long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population. , 2005, The Journal of general virology.

[6]  Yang Wang,et al.  Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus , 2005, Journal of Virology.

[7]  E. Rosenberg,et al.  Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Yang Wang,et al.  Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[9]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[10]  D. Shriner,et al.  Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses , 1997, Journal of virology.

[11]  O. Pybus,et al.  Unifying the Epidemiological and Evolutionary Dynamics of Pathogens , 2004, Science.

[12]  O. Turriziani,et al.  Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. , 2001, AIDS research and human retroviruses.

[13]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.

[14]  C. Rouzioux,et al.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  F. Roudot-thoraval,et al.  Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. , 1999, The Journal of infectious diseases.

[16]  Proviral HIV‐1 dynamics and evolution in patients receiving efficient long‐term antiretroviral combination therapy , 2000, HIV medicine.

[17]  F. Roudot-thoraval,et al.  Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. , 1997, Blood.

[18]  S. Ray,et al.  Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression , 1995, Journal of virology.

[19]  J. Mittler,et al.  Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. , 2001, AIDS research and human retroviruses.

[20]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[21]  D. Posada,et al.  Lack of temporal structure in the short term HIV-1 evolution within asymptomatic naïve patients. , 2007, Virology.

[22]  J. del Romero,et al.  Co-existence of recent and ancestral nucleotide sequences in viral quasispecies of human immunodeficiency virus type 1 patients. , 2004, The Journal of general virology.

[23]  P. Gilbert,et al.  Intrapatient Diversity and Its Correlation with Viral Setpoint in Human Immunodeficiency Virus Type 1 CRF02_A/G-IbNG Infection , 2002, Journal of Virology.

[24]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[25]  C. Rouzioux,et al.  Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection , 2000, AIDS.

[26]  Steven M. Wolinsky,et al.  Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection , 1996, Science.

[27]  D. Richman,et al.  Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. , 2001, Virology.

[28]  Sudhir Kumar,et al.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment , 2004, Briefings Bioinform..

[29]  S. Oka,et al.  In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression , 1997, Journal of virology.

[30]  R. Siliciano,et al.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. , 2000, The Journal of clinical investigation.

[31]  M. Clementi,et al.  Host-Specific Modulation of the Selective Constraints Driving Human Immunodeficiency Virus Type 1env Gene Evolution , 1999, Journal of Virology.

[32]  A. V. Bordería,et al.  Plasma RNA viral load is not associated with intrapatient quasispecies heterogeneity in HIV-1 infection , 2004, Archives of Virology.

[33]  L. Meyer,et al.  Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters , 2005, AIDS.

[34]  Steve Kaye,et al.  Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance , 2001, Journal of acquired immune deficiency syndromes.

[35]  N. Saksena,et al.  HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors , 2000, AIDS.

[36]  Alan S. Perelson,et al.  Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.

[37]  D. Richman,et al.  Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. , 2001, The Journal of infectious diseases.

[38]  J. Mullins,et al.  Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS , 1997, Journal of virology.

[39]  Anthony D Kelleher,et al.  First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. , 2003, Virology.

[40]  J. Margolick,et al.  Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[41]  Thomas C. Quinn,et al.  Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure , 2002, Journal of Virology.

[42]  J. Margolick,et al.  Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Richman,et al.  Human Immunodeficiency Virus Replication and Genotypic Resistance in Blood and Lymph Nodes after a Year of Potent Antiretroviral Therapy , 1998, Journal of Virology.

[44]  J. del Romero,et al.  Different evolutionary patterns are found within human immunodeficiency virus type 1-infected patients. , 2001, The Journal of general virology.

[45]  E. Santagostino,et al.  Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. , 1998 .

[46]  H. Schuitemaker,et al.  Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. , 2002, AIDS.

[47]  C. Kuiken,et al.  Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period , 1995, Journal of virology.

[48]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[49]  P. Lemey,et al.  Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort , 2005, Retrovirology.

[50]  Tara L. Kieffer,et al.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.

[51]  Thomas C. Quinn,et al.  Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads , 2004, Journal of Virology.

[52]  D. Pieniążek,et al.  HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[53]  A. Rodrigo,et al.  Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. , 1997, AIDS research and human retroviruses.

[54]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[55]  Amalio Telenti,et al.  Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. , 2002, AIDS.